Department of Neuroradiology, AONR Cardarelli, Via Antonio Cardarelli, 9, 80100, Naples, Italy.
Department of Diagnostic and Interventional Radiology, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Radiol Med. 2018 Jul;123(7):545-552. doi: 10.1007/s11547-018-0866-7. Epub 2018 Mar 5.
Distinction between treatment-related changes and tumour recurrence in patients who have received radiation treatment for brain metastases can be difficult on conventional MRI. In this study, we investigated the ability of dynamic susceptibility contrast (DSC) perfusion in differentiating necrotic changes from pathological angiogenesis and compared measurements of relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF) and K2, using a dedicated software.
Twenty-nine patients with secondary brain tumors were included in this retrospective study and underwent DSC perfusion MRI with a 3-month follow-up imaging after chemo- or radiation-therapy. Region-of-interests were drawn around the contrast enhancing lesions and measurements of rCBV, rCBF and K2 were performed in all patients. Based on subsequent histological examination or clinico-radiological follow-up, the cohort was divided in two groups: recurrent disease and stable disease. Differences between the two groups were analyzed using the Student's t test. Sensitivity, specificity and diagnostic accuracy of rCBV measurements were analyzed considering three different cut-off values.
Between patients with and without disease, only rCBV and rCBF values were significant (p < 0.05). The only cut-off value giving the best diagnostic accuracy of 100% was rCBV = 2.1 (sensitivity = 100%; specificity = 100%). Patients with tumor recurrence showed a higher mean value of rCBV (mean = 4.28, standard deviation = 2.09) than patients with necrotic-related changes (mean = 0.77, standard deviation = 0.44).
DSC-MRI appears a clinically useful method to differentiate between tumor recurrence, tumor necrosis and pseudoprogression in patients treated for cerebral metastases. Relative CBV using a cut-off value of 2.1 proved to be the most accurate and reliable parameter.
在接受脑部转移放疗的患者中,常规 MRI 很难区分治疗相关变化与肿瘤复发。本研究旨在通过专用软件评估动态磁敏感对比(DSC)灌注成像鉴别肿瘤坏死与病理性血管生成的能力,并比较相对脑血容量(rCBV)、相对脑血流量(rCBF)和 K2 的测量值。
回顾性纳入 29 例继发脑肿瘤患者,所有患者均在放化疗后 3 个月行 DSC 灌注 MRI 检查。在增强病变周围勾画感兴趣区(ROI),并在所有患者中测量 rCBV、rCBF 和 K2 值。根据后续的组织学检查或临床影像学随访,将患者分为复发组和稳定组。使用学生 t 检验分析两组间的差异。根据三种不同的截断值分析 rCBV 测量的敏感性、特异性和诊断准确性。
仅 rCBV 和 rCBF 值在疾病组和非疾病组之间有显著差异(p<0.05)。唯一具有 100%最佳诊断准确性的截断值为 rCBV=2.1(敏感性=100%;特异性=100%)。肿瘤复发患者的 rCBV 平均值(mean=4.28,standard deviation=2.09)显著高于肿瘤坏死相关改变患者(mean=0.77,standard deviation=0.44)。
DSC-MRI 是一种区分脑转移放疗后肿瘤复发、肿瘤坏死和假性进展的有临床应用价值的方法。使用 2.1 的截断值的相对 CBV 是最准确和可靠的参数。